Auragens Named Stem Cell Treatment Center of the Year 2026, Earning Back-to-Back Recognition for Leadership in Regenerative Medicine
Auragens has announced that it has been recognized as Stem Cell Treatment Center of the Year 2026 by Life Sciences Review, marking the second consecutive year the company has received the publication’s highest distinction. According to Auragens, it is the first organization to earn the award in back-to-back years, highlighting its continued focus on advancing regenerative medicine through an integrated model that combines scientific research, biologics manufacturing, physician-led clinical care, and quality management.
While the award acknowledges the organization’s commitment to patient care, Auragens views the recognition as a reflection of broader changes occurring across the regenerative medicine industry. As the field continues to evolve from an emerging area of research into a more mature medical discipline, the company believes long-term success will increasingly depend on scientific evidence, manufacturing quality, regulatory oversight, and integrated healthcare delivery rather than promotional claims alone.
The latest recognition reinforces Auragens’ long-term strategy of developing a comprehensive regenerative medicine platform designed to support innovation while maintaining rigorous oversight across research, manufacturing, and clinical practice.
Building an Integrated Regenerative Medicine Platform
Since its founding, Auragens has pursued a business model that differs from the traditional regenerative medicine clinic.
Rather than focusing solely on patient treatment, the company has invested in creating what it describes as a vertically integrated regenerative medicine enterprise. This model combines multiple capabilities—including scientific research, cellular manufacturing, physician-directed clinical care, quality systems, and translational medicine—within a single organizational framework.
The objective is to create continuity across every stage of regenerative therapy, from biologic development and manufacturing through clinical administration and patient follow-up.
By integrating these functions internally, Auragens aims to maintain greater consistency in product quality, clinical protocols, and scientific development while supporting ongoing innovation in regenerative medicine.
The company believes that this approach allows it to accelerate research and product development while maintaining comprehensive oversight throughout the entire treatment lifecycle.
Focus on Scientific Research
Scientific research forms one of the central pillars of Auragens’ organizational strategy.
According to the company, its investigators have contributed extensively to the growing body of regenerative medicine literature through peer-reviewed publications, educational resources, and international scientific presentations.
Auragens reports that its research team has produced more than 20 peer-reviewed scientific publications, covering various aspects of regenerative medicine and cellular therapy.
In addition to journal publications, the organization states that its leadership has authored five bestselling books addressing regenerative medicine, healthcare innovation, and related scientific topics.
Members of the organization have also presented original clinical findings and research at conferences throughout North America, South America, and Europe.
Among these presentations are invited sessions at the NASA ASCEND Conference, where emerging technologies and scientific innovations across multiple disciplines are discussed.
The company believes that active participation in scientific research helps strengthen the evidence base supporting regenerative medicine while promoting collaboration within the broader medical community.
Expanding Global Research Collaboration
Auragens also emphasizes the importance of international collaboration in advancing regenerative medicine.
The company reports working with a variety of organizations, including universities, government agencies, healthcare institutions, and international partners involved in scientific research and translational medicine.
These collaborations focus on expanding scientific understanding, supporting clinical innovation, and translating laboratory discoveries into practical healthcare applications.
By participating in multidisciplinary partnerships, Auragens seeks to contribute to the continued evolution of regenerative medicine while encouraging broader acceptance of evidence-based treatment approaches.
Such collaborations also provide opportunities to evaluate regenerative therapies across diverse patient populations and healthcare environments.
Advanced Cellular Manufacturing Capabilities
A distinguishing feature of Auragens’ operating model is its investment in on-site biologics manufacturing.
The company maintains an advanced cellular manufacturing laboratory responsible for producing stem cell-based biologic products under comprehensive quality management systems.
According to Auragens, the facility has manufactured more than 500 billion stem cells, supporting both clinical applications and ongoing research initiatives.
Maintaining manufacturing operations within the organization allows greater oversight of production processes, donor screening, quality assurance, and product consistency.
The company believes this vertical integration helps strengthen quality control while improving traceability throughout the biologics lifecycle.
Commitment to Quality Standards
Quality management represents another major component of Auragens’ infrastructure.
The organization operates an AABB-accredited Cellular Therapy Laboratory, reflecting adherence to internationally recognized quality standards for cellular therapy operations.
AABB accreditation is widely recognized within transfusion medicine and cellular therapy as an indicator of established quality systems covering laboratory operations, manufacturing practices, documentation, and patient safety.
By incorporating accredited laboratory operations into its broader regenerative medicine platform, Auragens aims to ensure that biologic products are manufactured under standardized procedures that support consistency and regulatory compliance.
The company considers quality management an essential component of advancing regenerative medicine as the field continues to mature.
Delivering Physician-Led Clinical Care
Beyond manufacturing and research, Auragens provides physician-directed regenerative medicine services for patients seeking advanced therapeutic options.
According to the company, individuals from more than 40 countries across six continents have traveled to receive treatment through its clinical programs.
Auragens states that its patient care model emphasizes individualized treatment planning supported by scientific evidence and measurable clinical outcomes.
The integrated structure allows physicians to coordinate closely with laboratory personnel and researchers throughout the treatment process.
This collaboration is intended to support continuity between biologic manufacturing, clinical decision-making, and patient follow-up while facilitating ongoing evaluation of treatment outcomes.
Supporting Elite Athletes
Auragens has also developed a reputation for providing regenerative medicine services to professional athletes.
The company reports treating athletes representing several major professional sports organizations, including participants from:
- National Football League (NFL)
- National Basketball Association (NBA)
- Major League Baseball (MLB)
- National Hockey League (NHL)
- PGA Tour
- Olympic competition
- International professional tennis
These athletes have sought regenerative therapies for injury recovery, musculoskeletal health, and performance support.
While sports medicine represents only one component of the company’s broader clinical activities, Auragens considers its work with elite athletes an example of the growing acceptance of regenerative medicine within high-performance healthcare.
Continuing Investment in Innovation
Auragens continues expanding its capabilities through investments in several strategic areas of regenerative medicine.
These initiatives include:
- Translational medical research
- Physician education
- Cellular manufacturing
- New biologic technologies
- Clinical program development
- Therapeutic innovation
One recent development highlighted by the company is the establishment of its dedicated Orthobiologics Division.
The new division focuses on regenerative approaches for musculoskeletal conditions and sports medicine applications, supporting the company’s broader objective of developing evidence-based biologic therapies.
Orthobiologics has become an increasingly active area of clinical research as physicians investigate regenerative approaches for joint disorders, tendon injuries, ligament damage, and other orthopedic conditions.
Recognition Across Multiple Areas
The latest Life Sciences Review award adds to a growing list of recognitions received by Auragens and its leadership over recent years.
According to the company, these honors include awards recognizing achievements in regenerative medicine, scientific research, innovation, business leadership, and entrepreneurship.
Among the distinctions cited are:
- Stem Cell Treatment Center of the Year (2025 and 2026)
- Regenerative Medicine Solutions Provider of the Year (2026)
- Most Innovative Company (2026)
- World’s Top 100 Innovators (2026)
- Business of the Year (2025)
- Healthcare CEO of the Year (2023 and 2026)
- Medical Researcher of the Year (2025)
- Visionary Healthcare Leader of the Year (2026)
- EY Entrepreneur of the Year (2026)
The company states that these recognitions reflect contributions extending beyond patient care into scientific publication, healthcare innovation, biologics manufacturing, and organizational leadership.
Regenerative Medicine Enters a New Phase
Auragens believes regenerative medicine is approaching an important period of industry development.
As research continues to expand and regulatory expectations evolve, the company anticipates greater emphasis on scientific validation, standardized manufacturing, published clinical evidence, and measurable treatment outcomes.
These factors are expected to become increasingly important for healthcare providers, patients, researchers, regulators, and industry partners evaluating regenerative medicine organizations.
The company argues that future leadership within the sector will depend less on marketing claims and more on demonstrated capabilities supported by transparent scientific evidence and operational excellence.
Following its second consecutive recognition as Stem Cell Treatment Center of the Year, Auragens plans to continue expanding its research collaborations, manufacturing capabilities, and clinical programs while strengthening its integrated regenerative medicine platform.
The company intends to build upon its existing investments in translational research, physician education, cellular therapy manufacturing, and patient-centered clinical care as demand for regenerative medicine continues to grow worldwide.
As the field advances, Auragens aims to contribute to the development of evidence-based regenerative therapies supported by scientific rigor, standardized quality systems, and multidisciplinary collaboration.
According to the company, the future of regenerative medicine will increasingly be shaped by measurable outcomes, validated research, and integrated healthcare delivery. Through continued innovation and investment across research, manufacturing, and clinical practice, Auragens seeks to help establish new benchmarks for excellence while supporting the ongoing evolution of regenerative medicine on a global scale.
About Auragens – Auragens is the market leader in the field of stem cell treatments, research, and development. As a complete regenerative medicine platform they operate their own laboratory onsite and are ISO certified, AABB Accredited and follow all cGMP guidelines and FDA related regulations for safety. Treatments are provided at their private state-of-the-art facility in Panama City, Panama and spans the entire 48th floor of a Class A office building in the Beverly Hills of Panama City, known as Punta Pacifica.
All science and medicine is overseen by a team of doctors hailing from universities such as Johns Hopkins, Stanford and Notre Dame among others. Published in numerous journals, recipient of Medical Researcher of the Year and Business of the Year, Auragens is leading in cutting edge Regenerative Medicine with a goal of making their treatments a Standard of Care and available to all in need.